Close Menu

NEW YORK (360Dx) – Opko Health announced today that it has received US Food and Drug Administration approval for its point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the company's Claros 1 Analyzer.

The test quantitatively measures total PSA in whole blood from a fingerstick of blood collected by a healthcare professional. It is used in conjunction with a digital rectal exam as an aid in the detection of prostate cancer in men aged 50 years or older. There are 25 million PSA tests performed in the US annually, according to Opko.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
21
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

May
22

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.